证券代码：300453 证券简称：三鑫医疗 公告编号：2025-057 江西三鑫医疗科技股份有限公司 2025 年第一次临时股东大会决议公告 2、本次股东大会不存在变更以往股东大会已通过的决议的情况。 一、会议召开和出席情况 （一）会议召开情况 1、召开时间： （1）现场会议召开时间为：2025 年 8 月 26 日下午 14:30-17:00 （2）网络投票时间为： 通过深圳证券交易所交易系统进行网络投票的时间为2025年8月26日上午 9:15-9:25，9:30-11:30，下午13:00-15:00； 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会不存在否决议案的情况。 通过深圳证券交易所互联网系统投票的时间为2025年8月26日上午9:15至下 午15:00的任意时间。 2、现场会议召开地点：江西省南昌县小蓝经济开发区富山大道999号江西三 鑫医疗科技股份有限公司二楼会议室 3、召开方式：现场表决与网络投票相结合的方式 4、会议召集人：公司董事会 5、现场会议主持人：董事长彭义兴先生 6、股权登记日：2025年8月20日 本次 ...

江西华邦律师事务所 关于江西三鑫医疗科技股份有限公司 2025年第一次临时股东大会的法律意见书 致：江西三鑫医疗科技股份有限公司 根据《中华人民共和国公司法》《中华人民共和国证券法》及《上市公司股 东会规则》(以下简称"《股东会规则》")以及深圳证券交易所《深圳证券交易 所上市公司股东会网络投票实施细则》(以下简称"《网络投票实施细则》") 等法律、法规、规范性文件及现时有效的《江西三鑫医疗科技股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，受江西三鑫医疗科技股份有限公司 （以下简称"公司"）委托，江西华邦律师事务所指派方世扬、谌文友律师出席 公司2025年第一次临时股东大会（以下简称"本次股东大会"），并为本次股东 大会出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的召开本次股东大会的有关 文件的原件或复印件，包括（但不限于）公司召开本次股东大会的通知公告，公 司本次股东大会的各项议程及相关决议等文件，同时听取了公司就有关事实的陈 述和说明。 本所律师根据《股东会规则》的有关规定，按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对公司本次股东大会的召集及召开等有关法律问题发 ...

Group 1 - The company, Sanxin Medical, stated on August 22 that it will disclose the number of shareholders at specific points in time in its periodic reports [2] - Detailed information regarding the number of shareholders and their holdings will be available in the section "Number of Company Shareholders and Shareholding Situation" of the periodic report [2]

Group 1 - The core point of the article is that Sanxin Medical has established a wholly-owned subsidiary in Hong Kong to enhance cooperation and expand its presence in international markets [1] - The registration procedures for the Hong Kong subsidiary have been completed, as detailed in the announcement published on July 29, 2025 [1] - The company will fulfill its information disclosure obligations in accordance with relevant regulations if there are plans to establish a company in Hainan in the future [1]

Core Viewpoint - Sanxin Medical announced on August 22 that it has established production capacity for blood dialysis products in Jiangxi, Yunnan, Sichuan, and Heilongjiang, with overall capacity utilization at a high level [1] Group 1: Production Capacity and Expansion - The company is steadily expanding its blood purification key product capacity through the construction of new production lines and additional production bases [1] - The newly expanded R&D and production base in Jiangxi has begun to gradually put some production lines into operation, providing capacity support for the collective procurement expansion [1] Group 2: Fundraising and Investment Projects - To further release key product capacity and better meet the steadily growing market demand, the company plans to issue convertible bonds to unspecified objects to raise no more than 530 million yuan [1] - After deducting issuance costs, the funds will be used for projects including the annual production of 10 million blood dialysis membranes and 10 million blood dialysis devices, as well as the construction of a new production line for 30 million sets of blood dialysis tubing [1] - Additional projects include the renovation of the Jiangxi Chengtu Kang electronic accelerator irradiation sterilization production line, aimed at enhancing the company's market competitiveness [1]

Core Viewpoint - Sanxin Medical (300453) emphasizes its commitment to an innovation-driven development strategy, focusing on a comprehensive product range for various blood purification treatment modalities [1] Product Development - The company has established a complete product system for end-stage renal disease blood purification, including hemodialysis, hemofiltration, and Continuous Renal Replacement Therapy (CRRT) [1] - Hemodialysis products include hemodialysis machines, dialyzers, dialysis concentrates, dialysis tubing, and disposable dialysis catheters, with ongoing upgrades to address patient pain points [1] - Hemofiltration products consist of hemofiltration machines, hemofiltration filters, and blood purification infusion tubing [1] - CRRT products include CRRT tubing and accessories, with accelerated development of CRRT equipment [1]

Core Viewpoint - Company is focusing on international expansion as a strategic initiative, leveraging the opportunity of "Chinese manufacturing" going global, and has successfully registered products in countries like Indonesia, Peru, and Mexico while accelerating certification processes in Turkey, Vietnam, and Brazil [1] Group 1: International Expansion - Company has established a global self-certification system to enhance its international market presence in the blood purification business, significantly improving its global competitiveness [1] - By the first half of 2025, the company achieved notable results in overseas market development, with overseas business revenue reaching 187 million yuan, representing a year-on-year growth of 67.30% [1] Group 2: Product Performance - Revenue from blood purification product exports reached 165 million yuan, accounting for 88% of total export revenue, with a year-on-year increase of 83.84% [1] - In the first half of 2025, export sales revenue of hemodialysis equipment grew by approximately 130%, while export sales revenue of hemodialysis consumables increased by about 70% [1] - The stable growth of key product exports has become a significant driver of the company's performance [1]

Core Insights - Company announced a projected revenue decline of approximately 15% for its drug delivery devices in the first half of 2025 compared to the previous year due to intensified market competition and product homogeneity [1] Company Strategy - The company is focusing on the blood purification sector as part of its strategic deployment [1] - Continuous product iteration and upgrades are planned, emphasizing safety, convenience, and precision in drug delivery devices [1] Market Trends - The aging population and increasing number of chronic disease patients are driving higher clinical demands for drug delivery devices in terms of safety, convenience, and precision [1] Product Development - The company is set to launch several new functional products, including precision filtration infusion, light-protective infusion, safe injection, and medical needle-free injection [1] - A new pre-filled catheter flushing device has been registered, extending the product line and providing safer and more efficient catheter care solutions for clinical treatment [1]

Core Viewpoint - Jiangxi Sanxin Medical Technology Co., Ltd. reported a revenue of 761 million yuan in the first half of 2023, marking a year-on-year increase of 10.83%, with a net profit of 115 million yuan, up 8.35% year-on-year [2] Group 1: Financial Performance - The company's net profit attributable to shareholders, excluding non-recurring gains and losses, was 103 million yuan, reflecting a year-on-year growth of 9.26% [2] - Revenue from blood purification products reached 626 million yuan, representing a year-on-year increase of 19.73%, accounting for 82.23% of total revenue [3] - The gross margin for blood purification products was 34.30%, showing an increase compared to the previous year [4] Group 2: Market Expansion - The company achieved significant breakthroughs in overseas markets, with international sales revenue reaching 187 million yuan, a year-on-year increase of 67.30% [6] - Blood purification product exports contributed 165 million yuan to overseas sales, accounting for 88% of total export revenue, with an increase of 83.84% year-on-year [6] - The company is focusing on emerging markets along the "Belt and Road" initiative, which have large and growing populations, providing substantial market opportunities [6] Group 3: Industry Trends - The global end-stage renal disease (ESRD) patient population is projected to grow from 11.14 million in 2023 to 13.29 million by 2027, with a compound annual growth rate of 4.51% [3] - The demand for blood purification products is expected to remain strong due to the increasing number of ESRD patients and the essential nature of these products in treatment [4][3]

Group 1 - The core viewpoint of the article is that Sanxin Medical (SZ 300453) held a research meeting with Manulife Fund and Wanjia Fund on August 21, 2025, where company executives addressed investor inquiries [1] - For the first half of 2025, Sanxin Medical's revenue composition was 99.78% from the medical device industry and 0.22% from other businesses [1]